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DESCRIPTION of CASE
A 
61-year-old male carpenter presented with ten months’ 
history of dyspepsia. More recently he had developed 
epigastric pain and had lost four kilograms in weight 
because of anorexia. He was otherwise asymptomatic and 
in particular there was no history of nausea, vomiting, 
abdominal distension, melaena, haematemesis, diarrhoea, 
constipation, night sweats, or fevers. There was no past 
medical history of note, and he had a performance status of 
zero (see Table 1). His only medication was lansoprazole. He 
drank no alcohol and smoked 40 cigarettes/day. Examination 
was unremarkable. All blood tests, including full blood count, 
biochemistry, and lactate dehydrogenase, were normal.
What Was the Differential Diagnosis at This Point?
The differential diagnosis in a patient with dyspepsia, 
epigastric pain, and weight loss is gastro-oesophageal reﬂ  ux, 
gastritis, gallstones, peptic ulcer, oesophageal/gastric 
carcinoma, lymphoma, and inﬂ  ammatory bowel disease.
The patient underwent an endoscopy which showed a 4–5-
cm ulcer with rolled edges on the greater curve of the antrum 
of the stomach. Appearances were suggestive of a malignant 
lesion. 
What Was the Most Likely Diagnosis?
The likely diagnosis was therefore either gastric carcinoma or 
lymphoma—most likely non-Hodgkin lymphoma (NHL)—
speciﬁ  cally, either gastric mucosa-associated lymphoid 
tissue (MALT) lymphoma or diffuse large B cell lymphoma 
(DLBCL).
Histology revealed a diagnosis of DLBCL (see Figures 1 
and 2). The biopsy was positive for surface markers CD20 and 
CD79a and surface immunoglobulin (IgM). These markers 
are found on B cells, and positivity conﬁ  rmed the B cell 
origin of the lymphoma (see Figures 3 and 4). The biopsy 
was negative for BCL-2 protein expression. Positive BCL-2 
expression is associated with an adverse prognosis. Staining 
for Helicobacter pylori antibody was negative.
Learning Forum
Open access, freely available online
June 2005  |  Volume 2  |  Issue 6  |  e154
The Learning Forum discusses an important clinical problem of relevance 
to a general medical audience.
A 61-Year-Old Man with Dyspepsia 
and Weight Loss
Catherine Burton
Citation: Burton C (2005) A 61-year-old man with dyspepsia and weight loss. PLoS 
Med 2(6): e154.
Copyright: © 2005 Catherine Burton. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited. 
Abbreviations: CT, computed tomography; DLBCL, diffuse large B cell lymphoma; 
IPI, international prognostic index; MALT, mucosa-associated lymphoid tissue; NHL, 
non-Hodgkin lymphoma
Catherine Burton is Clinical Research Fellow in the Department of Haematology, 
University College London, United Kingdom. E-mail: cb@ctc.ucl.ac.uk
Competing Interests: The author declares that she has no competing interests.
DOI: 10.1371/journal.pmed.0020154
Table 1. World Health Organization Performance Status 
Score Functional Ability
0 Able to carry out all normal activity without restriction
1 Restricted in physically strenuous activity but ambulatory 
and able to carry out light work
2 Ambulatory and capable of all self care but unable to carry 
out any work; up and about more than 50% of waking hours
3 Capable only of limited self care; conﬁ  ned to bed or chair 
more than 50% of waking hours
4 Completely disabled; cannot carry out any self care; totally 
conﬁ  ned to bed or chair
DOI: 10.1371/journal.pmed.0020154.t001
DOI: 10.1371/journal.pmed.0020154.g001
Figure 1. Low-Power Haematoxylin and Eosin Staining Showing DLBCL
DLBCL is composed of large transformed lymphoid cells, with 
oval to round nuclei with ﬁ  ne chromatin and membrane-bound 
nucleoli. Surface and/or cytoplasmic immunoglobulin (IgM 
> IgG > IgA) is demonstrated in 50%–75% of cases. BCL-2 is 
positive in approximately 30%–50% of cases and is associated 
with a poorer prognosis.
DOI: 10.1371/journal.pmed.0020154.g002
Figure 2. High-Power Haematoxylin and Eosin Staining Showing DLBCLPLoS Medicine  |  www.plosmedicine.org 0506
Which Further Investigations Were Indicated?
In view of the diagnosis of lymphoma, staging investigations 
were performed. Computed tomography (CT) imaging 
showed thickening of the gastro-oesophageal junction (see 
Figure 5). Multiple subcentimetre lymph nodes within the 
abdomen were also noted, but these were not enlarged by 
CT criteria. CT chest was normal. A bone marrow biopsy was 
normal.
The patient was therefore diagnosed with stage IE (see 
Table 2) DLBCL of the stomach. His international prognostic 
index (IPI) score was one (see Table 3).
What Was the Appropriate Treatment?
The patient was treated with R-CHOP chemotherapy 
(rituximab, cyclophosphamide, doxorubicin, vincristine, 
and prednisolone). He received four initial courses 
administered once every three weeks. His chemotherapy 
course was complicated by a hospital admission with 
Klebsiella pneumonia that responded well to antibiotics. 
After four courses of treatment he underwent a restaging 
CT and endoscopy. The CT scan showed improvement in 
the thickening of the gastro-oesophageal junction and no 
signiﬁ  cant lymphadenopathy (see Figure 6). The repeat 
endoscopy and biopsy were normal. 
The patient went on to have two further courses of 
consolidation R-CHOP chemotherapy. Repeat CT imaging 
after six courses of chemotherapy showed no further change 
in the thickening of the gastro-oesophageal junction. In view 
of the fact that there had been no further response between 
the fourth and sixth courses of chemotherapy and a biopsy 
had been negative, no further consolidation chemotherapy 
was given. The ﬁ  nal CT also showed collapse of the left lower 
lobe of the patient’s lung. In view of these ﬁ  ndings and the 
patient’s history of being a heavy smoker, he underwent a 
ﬁ  bre optic bronchoscopy. This revealed a mucus plug at 
the oriﬁ  ce of the left lower lobe, probably secondary to his 
previous pneumonia. The mucosa was normal. A repeat chest 
X ray showed re-inﬂ  ation of the left lower lobe of his lung.
At follow-up this patient remains well and asymptomatic 
and is gaining weight. His last blood tests were normal. He 
remains under standard review every three months. 
DISCUSSION
Symptoms of dyspepsia and epigastric pain are common, 
especially in the Western world. There is a one in ten lifetime 
risk for people in the Western world of developing a peptic 
ulcer [1]. If symptoms persist or clinical history is suggestive 
of signiﬁ  cant pathology, an endoscopy with biopsies is 
mandatory. Although not at the top of the list of differential 
diagnoses, this case highlights the fact that lymphoma needs 
to be considered as a possible diagnosis.
Non-Hodgkin Lymphoma
NHL is the 11th commonest malignancy worldwide. It 
is increasing in incidence, with more than 300,000 cases 
worldwide and 9,000 cases in the United Kingdom diagnosed 
each year [2]. DLBCL is the most frequently occurring NHL, 
constituting about one-third of all adult NHL [3]. There is a 
slight male predominance, and median age of presentation 
is in the seventh decade [3,4], as in this patient, although the 
age range is broad. 
Patients can present with nodal or extra-nodal disease. Up 
to 40% of cases are initially conﬁ  ned to extra-nodal sites [5]. 
The most common extra-nodal site is the gastrointestinal tract 
[5], especially the stomach, although any extra-nodal location 
can be a primary site. Lymphomas of the stomach can either 
be indolent MALT lymphoma or DLBCL, which may or may 
not be on the background of a MALT lymphoma. 
For MALT lymphoma the median age of presentation 
is in the seventh decade—median age is 61 years—with a 
slight female predominance [4]. There is a close association 
between gastric MALT lymphoma and Helicobacter pylori 
infection; over 90% of cases are H. pylori positive [6]. For 
MALT lymphoma, if the lesion is limited to the gastric 
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Figure 3. Strong CD20 Positivity
DLBCL usually expresses various pan-B markers, e.g. CD20 and 
CD79a.
DOI: 10.1371/journal.pmed.0020154.g004
Figure 4. High MIB-1 Expression
MIB-1 staining demonstrates proliferative activity of DLBCL. 
Proportion of cells stained is usually greater than 40%. 
Table 2. Ann Arbor Staging System
Stagea Location of Disease
I Disease in single lymph node region or lymphoid structure, e.g., 
spleen
II Disease in two or more regions on the same side of the diaphragm
III Disease in lymph node regions on both sides of the diaphragm
IV Diffuse or disseminated disease in one or more extralymphatic 
sites (e.g., liver and bone marrow) with or without lymph node 
involvement
aSufﬁ  x “E” added to the stage denotes involvement of extra-nodal organ or site. 
DOI: 10.1371/journal.pmed.0020154.t002PLoS Medicine  |  www.plosmedicine.org 0507
mucosa, eradication of the bacteria with triple antibiotic 
therapy is often sufﬁ  cient to cause regression of the 
lymphoma [7,8], whereas DLBCL also requires treatment 
with chemotherapy.
Use of the IPI score [9], deﬁ  ned by clinical prognostic 
factors, is currently the standard approach to stratify patient 
risk in DLBCL (see Table 3). Difference in outcome, though, 
between groups of patients with similar IPI scores indicates 
that DLBCL encompasses a clinically and biologically 
heterogeneous group of tumours, which vary in response to 
chemotherapy. Combining the IPI risk score with cellular and 
molecular markers may improve patient risk stratiﬁ  cation at 
presentation. For example, germinal cell phenotype, deﬁ  ned 
by BCL-6 and CD10 positivity, has been associated with a 
better outcome [10,11], and BCL-2 protein expression has 
been shown to be predictive of a worse outcome [11–15]. 
Both have been demonstrated immunohistochemically and 
conﬁ  rmed by gene microarray analysis [16–18]. Combining 
cellular prognostic factors with the IPI is likely to become 
increasingly important in predicting outcome and tailoring 
therapy for DLBCL [19].
Treatment of DLBCL
DLBCL is an aggressive lymphoma but potentially curable. 
Treatment for DLBCL is combination chemotherapy 
plus the monoclonal antibody rituximab [20]. CHOP 
chemotherapy (cyclophosphamide, doxorubicin, vincristine, 
and prednisolone) is given every three weeks. Rituximab 
is a chimeric monoclonal antibody containing human IgG 
lambda and kappa constant regions with murine variable 
regions, which has a high afﬁ  nity for the CD20 antigen. 
A dose of 375 mg/m2 given every three weeks with CHOP 
chemotherapy is now considered standard therapy for 
DLBCL. The mechanisms of action of anti-CD20 antibody are 
multiple and include induction of antibody-dependent cell-
mediated cytotoxicity, induction of complement-mediated 
lysis, induction of apoptosis, and sensitisation of resistant 
lymphoma cells to chemotherapeutic agents. 
Rituximab and CHOP chemotherapy have non-overlapping 
toxic effects, with emerging evidence of synergy [20,21]. 
The French GELA group (Groupe d’Etude des Lymphomes 
de l’Adulte) showed that addition of rituximab to CHOP 
(R-CHOP) had signiﬁ  cant activity in elderly patients newly 
diagnosed with DLBCL [20]. CHOP plus rituximab was 
associated with signiﬁ  cantly better overall response rate 
(94%), complete response rate (76%), event-free survival, 
and overall survival than CHOP alone. This survival advantage 
in elderly patients (>60 years) with DLBCL following R-CHOP 
represents the ﬁ  rst major therapeutic advance for this group 
of patients since the introduction of CHOP nearly 30 years 
ago. Recent studies show similar beneﬁ  ts in younger patients 
[21,22], so rituximab in combination with CHOP should be 
used for all newly diagnosed patients with DLBCL.
Toxicity of Chemotherapy
General toxicity associated with chemotherapy includes 
mucositis, gastrointestinal disturbance, myelosuppression 
(increasing the risk of infections and bleeding), alopecia, 
parathesiae, and infertility. Speciﬁ  c side effects of 
chemotherapeutic agents used for treating NHL are shown in 
Table 4. 
Side effects of rituximab include fevers, headache, nausea, 
lethargy, myalgia, arthralgia, skin erythema, pruritus, and 
hypotension. Most of these symptoms disappear upon 
temporary slowing or discontinuation of the treatment 
or after the administration of paracetamol and/or anti-
allergic medication. Fatalities following severe cytokine 
release syndrome—which is characterised by severe 
shortness of breath and associated with features of tumour 
lysis syndrome—have occurred 1–2 hours after infusion of 
rituximab([23], Section 8.2.3; [24]). Patients with a high 
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Figure 5. CT at Diagnosis Showing Thickening of Gastro-Oesophageal 
Junction and Stomach Wall
DOI: 10.1371/journal.pmed.0020154.g006
Figure 6. Post-Treatment CT Showing Almost Complete Resolution of 
the Abnormal Thickening of Gastro-Oesophageal Junction and Stomach 
Wall
Table 3. International Prognostic Index
Risk Group Risk Scorea Five-Year Survival Rate (%)
Low risk 0 or 1 73
Low intermediate 2 51
High intermediate 3 43
High 4 or 5 26
Source: [9]. 
aFive clinical features at presentation, indicative of a poor prognosis, used in calculating the IPI score are age greater 
than 60, Ann Arbor stage III or IV, elevated serum lactate dehydrogenase, performance status 2–4, and having more 
than one extra-nodal disease site. One point is given for each criterion met. Patients are assigned to one of four risk 
groups on the basis of their number of presenting risk factors. 
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tumour burden as well as those with pulmonary insufﬁ  ciency 
or inﬁ  ltration are at increased risk and should be monitored 
very closely, and a slower rate of infusion should be 
considered as necessary. 
Related to this case in particular, patients with gastric ulcers 
are at risk of perforation on initiation of treatment. Such 
patients should receive proton-pump inhibitor prophylaxis 
during chemotherapy. There is a need for close observation 
when chemotherapy is started, but the presence of a gastric 
ulcer is not an indication for dose reduction.
Monitoring Response to Chemotherapy
Response to chemotherapy needs to be monitored on a 
regular basis. Patients should be restaged after four courses 
of R-CHOP chemotherapy with CT scanning. If the bone 
marrow was involved at diagnosis, then a repeat biopsy is 
required. In cases such as our patient where disease was 
apparent elsewhere, a repeat biopsy of that lesion should be 
performed. 
In the UK, standard practice for those in complete 
remission with no evidence of disease is to receive a further 
two courses of R-CHOP consolidation. Those in partial 
remission (≥50% improvement) after four courses are 
restaged after six courses, and if they are improving they 
go on to receive two further courses of R-CHOP. If there 
is no further improvement, consolidation radiotherapy is 
considered. Those in partial remission after four courses with 
no further improvement after six courses of R-CHOP receive 
consolidation radiotherapy or are considered for second-line 
treatment with an alternative regimen containing different 
chemotherapeutic agents. 
Practice elsewhere in Europe varies, with up to eight 
courses of R-CHOP being given regardless of remission 
status. Although not universally available, FDG-PET (2-
ﬂ  uoro-2-deoxy-d-glucose positron emission tomography) is 
a functional imaging technique that is currently the most 
accurate modality to identify residual disease and differentiate 
it from scar tissue in patients with residual radiological 
abnormalities [25–27]. In general, re-biopsy of suspicious 
lesions should be considered.  
References
1.  Calam J (2003) Peptic ulcer disease. In: Warrell D, Cox T, Firth J, Benz E, 
editors. Oxford textbook of medicine, 4th ed. Oxford: Oxford University 
Press. pp. 558–568.
2.  Ferlay J, Bray F, Pisani P, Harkin D (2004) GLOBOCAN 2002—Cancer 
incidence, mortality and prevalence worldwide, version 2. IARC CancerBase 
No. 5 [computer program]. Lyon: IARCPress.
3.  Armitage J, Weisenburger D (1998) New approach to classifying non-
Hodgkin’s lymphomas: Clinical features of the major histologic subtypes. 
Non-Hodgkin’s Lymphoma Classiﬁ  cation Project. J Clin Oncol 16: 2780–
2795.
4.  The Non-Hodgkin’s Lymphoma Classiﬁ  cation Project (1997) A clinical 
evaluation of the International Lymphoma Study Group classiﬁ  cation of 
non-Hodgkin’s lymphoma. Blood 89: 3909–3918.
5.  Harris N, Jaffe E, Stein H, Banks P, Chan J, et al. (1994) A revised 
European-American classiﬁ  cation of lymphoid neoplasms: A proposal from 
the International Lymphoma Study Group. Blood 84: 1361–1392.
6.  Wotherspoon A, Ortiz-Hidalgo C, Falzon M, Isaacson P (1991) Helicobacter 
pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 338: 
1175–1176.
7.  Bayerdörffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, et al. 
(1995) Regression of primary gastric lymphoma of mucosa-associated 
lymphoid tissue type after cure of Helicobacter pylori infection. Lancet 
345: 1591–1594.
8.  Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M (2004) 
Long term outcome of patients with gastric marginal zone B cell lymphoma 
of mucosa associated lymphoid tissue (MALT) following exclusive 
Helicobacter pylori eradication therapy: Experience from a large prospective 
series. Gut 53: 34–37.
9.  (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. The 
International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl 
J Med 329: 987–994.
10. Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, et al. (2000) Distinct types 
of diffuse large B-cell lymphoma identiﬁ  ed by gene expression proﬁ  ling. 
Nature 403: 503–511.
11. Barrans S, Carter I, Owen R, Davies F, Patmore R, et al. (2002) Germinal 
center phenotype and bcl-2 expression combined with the International 
Prognostic Index improves patient risk stratiﬁ  cation in diffuse large B-cell 
lymphoma. Blood 99: 1136–1143.
12. Hermine O, Haioun C, Lepage E, d’Agay M, Briere J, et al. (1996) 
Prognostic signiﬁ  cance of bcl-2 protein expression in aggressive non-
Hodgkin’s lymphoma. Groupe d’Etude des Lymphomes de l’Adulte 
(GELA). Blood 87: 265–272.
13. Kramer M, Hermans J, Parker J, Krol A, Kluin-Nelemans J, et al. (1996) 
Clinical signiﬁ  cance of bcl2 and p53 protein expression in diffuse large B-
cell lymphoma: A population-based study. J Clin Oncol 14: 2131–2138.
14. Hill M, MacLennan K, Cunningham D, Vaughan Hudson B, Burke M, et 
al. (1996) Prognostic signiﬁ  cance of BCL-2 expression and bcl-2 major 
breakpoint region rearrangement in diffuse large cell non-Hodgkin’s 
lymphoma: A British National Lymphoma Investigation Study. Blood 88: 
1046–1051.
15. Gascoyne R, Adomat S, Krajewski S, Krajewska M, Horsman D, et al. 
(1997) Prognostic signiﬁ  cance of Bcl-2 protein expression and Bcl-2 gene 
rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood 90: 
244–251.
16. Hans C, Weisenberger D, Greiner T, Gascoyne R, Delabie J, et al. (2004) 
Conﬁ  rmation of the molecular classiﬁ  cation of diffuse large B-cell 
lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 
275–282.
17. Lossos I, Czerwinski D, Alizadeh A, Wechser M, Tibshirani R, et al. (2004) 
Prediction of survival in diffuse large B-cell lymphoma based on the 
expression of six genes. N Engl J Med 350: 1828–1837.
18. Rosenwald A, Wright G, Chan W, Connors J, Campo E, et al. (2002) The 
use of molecular proﬁ  ling to predict survival after chemotherapy for diffuse 
large B-cell lymphoma. N Engl J Med 346: 1937–1947.
19. Mounier N, Briere J, Gisselbrecht C, Emile J, Lederlin P, et al. (2003) 
Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance 
to chemotherapy in elderly patients with diffuse large B-cell lymphoma 
(DLBCL). Blood 101: 4279–4284.
Table 4. Speciﬁ  c Side Effects of Chemotherapeutic Agents Used 
for Treating NHL
Chemotherapeutic Agent Speciﬁ  c Side Effect
Cyclophosphamide Haemorrhagic  cystitis
Doxorubicin Palpitations,  cardiomyopathy
Vincristine  Sensory and motor nerve damage, paralytic 
ileus
Prednisolone  Dyspepsia, peptic ulceration, acute 
pancreatitis, myalgia, hyperglycaemia, 
psychiatric disturbance, cataracts
DOI: 10.1371/journal.pmed.0020154.t004
Learning Points
• In all patients a careful history of the nature of the dyspepsia 
and the associated symptoms should be taken. All patients over 
45 years with dyspepsia should have an endoscopy performed. 
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